Search: WFRF:(Ruuth Kristina)
> (2010-2014) >
Activating ALK muta...
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
-
- Schönherr, Christina (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Ruuth, Kristina (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Yamazaki, Yasuo (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
show more...
-
- Eriksson, Therese (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Christensen, James (author)
- Pfizer Global Research and Development, Department of Research Pharmacology, La Jolla Laboratories, La Jolla, CA 92121, U.S.A.
-
- Palmer, Ruth H (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Hallberg, Bengt (author)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
show less...
-
(creator_code:org_t)
- 2011
- 2011
- English.
-
In: Biochemical Journal. - 0264-6021 .- 1470-8728. ; 440, s. 405-413
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Mutations in the kinase domain of ALK (anaplastic lymphoma kinase) have recently been shown to be important for the progression of the childhood tumour neuroblastoma. In the present study we investigate six of the putative reported constitutively active ALK mutations, in positions G1128A, I1171N, F1174L, R1192P, F1245C and R1275Q. Our analyses were performed in cell-culture-based systems with both mouse and human ALK mutant variants and subsequently in a Drosophila melanogaster model system. Our investigation addressed the transforming potential of the putative gain-of-function ALK mutations as well as their signalling potential and the ability of two ATP-competitive inhibitors, Crizotinib (PF-02341066) and NVP-TAE684, to abrogate the activity of ALK. The results of the present study indicate that all mutations tested are of an activating nature and thus are implicated in tumour initiation or progression of neuroblastoma. Importantly for neuroblastoma patients, all ALK mutations used in the present study can be blocked by the inhibitors, although some mutants exhibited higher levels of drug sensitivity than others.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
Keyword
- anaplastic lymphoma kinase (ALK)
- cancer
- Crizotinib
- gain-of-function mutation
- neuroblastoma
- NVP-TAE684
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database